XML 24 R11.htm IDEA: XBRL DOCUMENT
v3.20.2

REVENUES | 9 Months Ended
--- | ---
Sep. 30, 2020
REVENUES |
REVENUES | NOTE 4 – REVENUES The following table summarizes the Company’s disaggregation of revenues: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Nine Months Ended September 30, | ​
(U.S. dollars in thousands) |  | 2020 |  | 2019 | ​
Pfizer | ​ | $ | 5,844 | ​ | $ | 4,701 | ​
Brazil | ​ | $ | 6,000 | ​ | $ | 7,385 | ​
Chiesi | ​ | $ | 131 | ​ | $ | — | ​
Total revenues from selling goods | ​ | $ | 11,975 | ​ | $ | 12,086 | ​
Revenues from license and R&D services | ​ | $ | 31,428 | ​ | $ | 24,848 | ​
​ During the nine months ended September 30, 2020, the Company recorded revenue in the amount of $6.7 million following a change in estimate of the total costs expected to be incurred in the connection with the Chiesi Agreements. On March 16, 2020, the Company agreed to conduct a feasibility study with Kirin Holdings Company, Limited (“Kirin”) to evaluate the production of a novel complex protein utilizing ProCellEx®, the Company’s proprietary plant cell-based protein expression system. Kirin will bear the costs of conducting cell line engineering and protein expression studies on the target protein. In addition, the contract provides Kirin with an option to a future service for which the Company received a non-refundable payment in the amount of $1.0 million. The Company will recognize such amount as revenues when the aforementioned future services are performed or when the option expires.

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration